Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein

PLoS One. 2024 Apr 9;19(4):e0301773. doi: 10.1371/journal.pone.0301773. eCollection 2024.

Abstract

Respiratory syncytial virus (RSV) is the leading viral cause of bronchiolitis and pneumonia in infants and toddlers, but there currently is no licensed pediatric vaccine. A leading vaccine candidate that has been evaluated for intranasal immunization in a recently completed phase 1/2 clinical trial is an attenuated version of RSV strain A2 called RSV/ΔNS2/Δ1313/I1314L (hereafter called ΔNS2). ΔNS2 is attenuated by deletion of the interferon antagonist NS2 gene and introduction into the L polymerase protein gene of a codon deletion (Δ1313) that confers temperature-sensitivity and is stabilized by a missense mutation (I1314L). Previously, introduction of four amino acid changes derived from a second RSV strain "line 19" (I79M, K191R, T357K, N371Y) into the F protein of strain A2 increased the stability of infectivity and the proportion of F protein in the highly immunogenic pre-fusion (pre-F) conformation. In the present study, these four "line 19" assignments were introduced into the ΔNS2 candidate, creating ΔNS2-L19F-4M. During in vitro growth in Vero cells, ΔNS2-L19F-4M had growth kinetics and peak titer similar to the ΔNS2 parent. ΔNS2-L19F-4M exhibited an enhanced proportion of pre-F protein, with a ratio of pre-F/total F that was 4.5- to 5.0-fold higher than that of the ΔNS2 parent. The stability of infectivity during incubation at 4°C, 25°C, 32°C and 37°C was greater for ΔNS2-L19F-4M; for example, after 28 days at 32°C, its titer was 100-fold greater than ΔNS2. ΔNS2-L19F-4M exhibited similar levels of replication in human airway epithelial (HAE) cells as ΔNS2. The four "line 19" F mutations were genetically stable during 10 rounds of serial passage in Vero cells. In African green monkeys, ΔNS2-L19F-4M and ΔNS2 had similar growth kinetics, peak titer, and immunogenicity. These results suggest that ΔNS2-L19F-4M is an improved live attenuated vaccine candidate whose enhanced stability may simplify its manufacture, storage and distribution, which merits further evaluation in a clinical trial in humans.

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Child
  • Chlorocebus aethiops
  • Humans
  • Mutation, Missense
  • Respiratory Syncytial Virus Infections*
  • Respiratory Syncytial Virus Vaccines* / genetics
  • Respiratory Syncytial Virus, Human* / genetics
  • Vero Cells
  • Viral Fusion Proteins / genetics

Substances

  • Respiratory Syncytial Virus Vaccines
  • Antibodies, Viral
  • Viral Fusion Proteins
  • Antibodies, Neutralizing

Grants and funding

This study was funded in part by Sanofi. This research was also supported in part by the Division of Intramural Research of the NIAID, NIH. U.J.B., C. Luongo, L.Y., and P.L.C. were supported by a Collaborative Research and Development Agreement with Sanofi on the development of RSV vaccines.